全文获取类型
收费全文 | 503篇 |
免费 | 22篇 |
专业分类
儿科学 | 4篇 |
妇产科学 | 7篇 |
基础医学 | 42篇 |
口腔科学 | 2篇 |
临床医学 | 18篇 |
内科学 | 77篇 |
皮肤病学 | 9篇 |
神经病学 | 27篇 |
特种医学 | 16篇 |
外科学 | 76篇 |
综合类 | 6篇 |
预防医学 | 20篇 |
眼科学 | 2篇 |
药学 | 16篇 |
肿瘤学 | 203篇 |
出版年
2024年 | 1篇 |
2023年 | 2篇 |
2022年 | 6篇 |
2021年 | 13篇 |
2020年 | 5篇 |
2019年 | 13篇 |
2018年 | 17篇 |
2017年 | 8篇 |
2016年 | 3篇 |
2015年 | 15篇 |
2014年 | 16篇 |
2013年 | 14篇 |
2012年 | 29篇 |
2011年 | 33篇 |
2010年 | 28篇 |
2009年 | 9篇 |
2008年 | 19篇 |
2007年 | 20篇 |
2006年 | 19篇 |
2005年 | 24篇 |
2004年 | 25篇 |
2003年 | 27篇 |
2002年 | 21篇 |
2001年 | 12篇 |
2000年 | 24篇 |
1999年 | 28篇 |
1998年 | 6篇 |
1997年 | 6篇 |
1996年 | 1篇 |
1995年 | 7篇 |
1994年 | 5篇 |
1993年 | 3篇 |
1992年 | 24篇 |
1991年 | 15篇 |
1990年 | 4篇 |
1989年 | 7篇 |
1988年 | 3篇 |
1987年 | 5篇 |
1986年 | 1篇 |
1984年 | 1篇 |
1967年 | 1篇 |
1957年 | 1篇 |
1947年 | 2篇 |
1936年 | 1篇 |
1929年 | 1篇 |
排序方式: 共有525条查询结果,搜索用时 15 毫秒
1.
Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors 总被引:1,自引:0,他引:1
Ninety-nine patients with primary recurrent malignant tumors of the central nervous system were treated with procarbazine as a single agent. Procarbazine was not given as a specified protocol, but for patients who were ineligible or refused other protocols. All patients had been treated previously with radiotherapy and 96 patients had also received previous chemotherapy. Twenty-five patients were treated at the first progression of their tumor, 47 were treated at the second progression, and 27 were treated at the third progression of their tumor. For the aggregate, the response plus stabilization rate was 27% for glioblastoma multiforme with median time to tumor progression of 30 weeks, and 28% for other anaplastic gliomas with a median time to tumor progression of 49 weeks. With respect to the percent of patients who responded or stabilized to treatment, these results are inferior to those reported previously for patients treated with procarbazine at recurrence. With respect to duration of response and stabilization, the data are comparable. 相似文献
2.
Mayte Ramirez Francisco Garcí a-Rí o Aleydis Vi as Concepci n Prados Jos M. Pino Jos Villamor 《The Journal of asthma》2005,41(1):109-116
The study objectives were to analyze the changes in exhaled carbon monoxide (COex) induced by histamine provocation challenge in asthmatic patients and to evaluate the relationship between COex and airway sensitivity and reactivity. Levels of COex were measured in 105 nonsmoking mildly asthmatic subjects before and after histamine provocation challenge. Dose-response curves were characterized by their sensitivity (PD20) and reactivity. Dose-response slope (DRS), continuous index of responsiveness (CIR), and bronchial reactivity index (BRI) were determined as reactivity indices. Bronchial challenge was positive for 47 subjects and negative for 58. The COex levels rose significantly after bronchial challenge in the positive response group (4.49 ± 0.4 vs. 5.74 ± 0.57 ppm, p = 0.025) and in the negative response group (2.84 ± 0.25 vs 4.00 ± 0.41 ppm, p = 0.000). An inverse relation between basal COex and PD20 was found (r = - 0.318, p = 0.030). In all subjects, a proportional direct relationship between COex and DRS (r = 0.214, p = 0.015), CIR (r = 0.401, p = 0.000), and BRI (r = 0.208, p = 0.012) was observed. On stepwise multiple linear regression analysis, COex only significantly correlated with CIR (multiple r2 = 0.174, p = 0.000). In conclusion, exhaled CO determination is a noninvasive inflammatory marker of the respiratory tract, which shows an acceptable association with airway hyperresponsiveness. 相似文献
3.
A rare case of a patient with Laurence-Moon-Biedl syndrome associated with hypothalamic hamartoma is described. The English-language literature contains no cases of patients with this association. The clinical manifestations of this syndrome, those of hypothalamic hamartomas, and the appearance of the tumors on magnetic resonance images are discussed. 相似文献
4.
M. Jiménez-Mejías C. Pichardo-Guerrero F. Márquez-Rivas D. Martín-Lozano T. Prados J. Pachón 《European journal of clinical microbiology & infectious diseases》2002,21(3):212-214
Described here is a case of meningitis caused by multidrug-resistant Acinetobacter baumannii susceptible only to colistin, which was treated successfully with intravenous colistin sulfomethate sodium (5 mg/kg/day).
The levels of colistin in serum and cerebrospinal fluid and the pharmacokinetic/pharmacodynamic parameters of colistin were
determined. In this case, intravenously administered colistin penetrated cerebrospinal fluid (25% of serum levels) at levels
sustaining bactericidal concentrations.
Electronic Publication 相似文献
5.
Timothy F Cloughesy John Kuhn H Ian Robins Lauren Abrey Patrick Wen Karen Fink Frank S Lieberman Minesh Mehta Susan Chang Alfred Yung Lisa DeAngelis David Schiff Larry Junck Morris Groves Steve Paquette John Wright Kathleen Lamborn Said M Sebti Michael Prados 《Journal of clinical oncology》2005,23(27):6647-6656
PURPOSE: To determine the maximum-tolerated dose (MTD), toxicities, and clinical effect of tipifarnib, a farnesyltransferase (FTase) inhibitor, in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs (EIAEDs). This study compares the pharmacokinetics and pharmacodynamics of tipifarnib at MTD in patients on and off EIAEDs. PATIENTS AND METHODS: Recurrent malignant glioma patients were treated with tipifarnib using an interpatient dose-escalation scheme. Pharmacokinetics and pharmacodynamics were assessed. RESULTS: Twenty-three assessable patients taking EIAEDs received tipifarnib in escalating doses from 300 to 700 mg bid for 21 of 28 days. The dose-limiting toxicity was rash, and the MTD was 600 mg bid. There were significant differences in pharmacokinetic parameters at 300 mg bid between patients on and not on EIAEDs. When patients on EIAEDs and not on EIAEDs were treated at MTD (600 and 300 mg bid, respectively), the area under the plasma concentration-time curve (AUC)(0-12 hours) was approximately two-fold lower in patients on EIAEDs. Farnesyltransferase inhibition was noted at all tipifarnib dose levels, as measured in peripheral-blood mononuclear cells (PBMC). CONCLUSION: Toxicities and pharmacokinetics differ significantly when comparing patients on or off EIAEDs. EIAEDs significantly decreased the maximum concentration, AUC(0-12 hours), and predose trough concentrations of tipifarnib. Even in the presence of EIAEDs, the levels of tipifarnib were still sufficient to potently inhibit FTase activity in patient PBMCs. The relevance of these important findings to clinical activity will be determined in ongoing studies with larger numbers of patients. 相似文献
6.
7.
8.
Cristina Lalmolda Hector Prados Georgina Mateu Mariona Noray Xavier Pomares Manel Luján 《Archivos de bronconeumologia》2019,55(5):246-251
IntroductionThe aim of this study was to assess several air-pressure settings for MI–E to determine their effect on peak cough flow (PCF), and to compare the best pressures with those are more common used in the literature (±40 cmH2O) in patients with neuromuscular disorders (NMD).MethodsAdults with NMD in whom MI–E was indicated were recruited. Assisted PCF was measured by an external pneumotachograph. The protocol included 9 PCF measures per patient: 1 baseline (non-assisted), 4 with increasing inspiratory pressures without negative pressure (10, 20, 30 and 40 cmH2O or maximum tolerated), and then 4 adding expiratory pressures (?10, ?20, ?30 and ?40 cmH2O or maximum tolerated) with maximum inspiratory pressure previously achieved.ResultsTwenty one patients were included, 61% with amyotrophic lateral sclerosis (ALS). Mean PCFs with recommended pressures (±40 cmH2O) were lower than the scored in the individualized steps of the titration protocol (197.7 ± 67 l/min vs 214.2 ± 60 l/min, p < 0.05). Regarding subgroups, mean PCFmax values in ALS patients with bulbar symptoms were significantly higher than those achieved with recommended pressures (163.6 ± 80 vs 189 ± 66 l/min, p < 0.05).ConclusionThe PCFmax obtained with the protocol did not always match the recommended settings. It may be advisable to perform MI–E titration assessed by non-invasive PCF monitoring in patients with NMD, especially in ALS with bulbar involvement to improve the therapy detecting airway collapse induced by high pressures. 相似文献
9.